Real-world treatment patterns of patients with acute coronary syndrome based on 15-year data
- Authors: Egorova I.S.1, Vezikova N.N.1
-
Affiliations:
- Petrozavodsk State University
- Issue: Vol 15, No 4 (2024)
- Pages: 320-328
- Section: Original study articles
- URL: https://journals.rcsi.science/2221-7185/article/view/281638
- DOI: https://doi.org/10.17816/CS630570
- ID: 281638
Cite item
Full Text
Abstract
BACKGROUND: About half a million cases of acute coronary syndrome (ACS) are diagnosed in Russia every year. However, despite optimized treatment of patients with ACS, mortality remains high, which dictates the need to analyze the effectiveness of therapeutic measures.
AIM: To evaluate the real-world clinical features, treatment approaches, and outcomes in patients with ACS based on data from the long-term registry of the Regional Vascular Center.
MATERIALS AND METHODS: The study included consecutive 8 347 patients admitted to the Regional Vascular Center of the Republic of Karelia for ACS in 2008–2023. The clinical features, drug therapy, reperfusion interventions, complication rate, outcomes, and mortality were evaluated. The effectiveness of therapeutic measures in patients with ACS was analyzed using the obtained data and a 15-year real-world register.
RESULTS: The study included 8 247 patients, and there were more men (4 989 patients; 60.5%); 1 502 (18%) patients had a history of myocardial infarction; 4 741 (56.8%) were diagnosed with non-ST-segment elevation acute coronary syndrome (NSTE-ACS). In the study group, 4 481 (53.7%) emergency percutaneous coronary interventions (PCI) were performed for ACS. For ST-segment elevation acute coronary syndrome (STEACS), 2 928 (81.2%) patients had PCI, and 228 (7.8%) patients had thrombolytic therapy followed by PCI. Thrombolysis was performed in 113 (43%) and 150 (57%) patients before and after hospitalization, respectively. Efficacy criteria were determined in 57 (50.4%) and 107 (71.3%) patients with pre- and in-hospital interventions, respectively. Analysis of drug therapy for ACS showed that aspirin was prescribed in 8 255 (98.9%), β-blockers in 7 671 (91.9%), and statins in 8 138 (97.5%) cases. Life-threatening complications occurred in 1 out of 3 patients with STEACS and 1 out of 7 patients with NSTE-ACS. Cardiac arrest (p <0.0001), myocardial rupture (p=0.001), arrhythmias (p <0.0001), and cardiogenic shock (p <0.0001) were significantly more common in patients with STEACS, and pulmonary edema (p=0.005) was significantly more common in patients with NSTE-ACS. Hospital mortality was significantly higher in STEACS patients (p <0.0001).
The most common ACS outcome was myocardial infarction (2 955 (35.4%) patients with Q-wave MI and 2 045 (24.5%) patients with non-Q-wave MI). Unstable angina was diagnosed in 1 569 (18.8%) patients.
CONCLUSION: Fifteen-year register data showed a high percentage of reperfusion interventions for ACS and prescription of drugs that improve the prognosis. A high percentage of life-threatening complications was noted, especially in STEACS; however, hospital mortality is low if proper treatment is provided.
Full Text
##article.viewOnOriginalSite##About the authors
Inga S. Egorova
Petrozavodsk State University
Author for correspondence.
Email: inga.skopets@gmail.com
ORCID iD: 0000-0002-5157-5547
SPIN-code: 4981-2363
MD, Cand. Sci. (Medicine), Associate Professor
Russian Federation, 33 Lenin avenue, 185910 PetrozavodskNatalia N. Vezikova
Petrozavodsk State University
Email: inga.skopets@gmail.com
ORCID iD: 0000-0002-8901-3363
MD, Dr. Sci. (Medicine), Professor
Russian Federation, 33 Lenin avenue, 185910 PetrozavodskReferences
- Boytsov SA, Alekyan BG, Shakhnovich RM, Ganyukov VI. What is changing in the treatment of acute coronary syndrome in the Russian Federation? Rational Pharmacotherapy in Cardiology. 2022;18(6):703–709. EDN: IZOSDM doi: 10.20996/1819-6446
- Kontsevaya AV, Kalinina AM, Koltunov IE, Oganov RG. Socio-economic damage by acute coronary syndrome in Russian Federation. Rational Pharmacotherapy in Cardiology. 2011;7(2):158–166. EDN: OXISHJ doi: 10.20996/1819-6446-2011-7-2-158-166
- Clinical practice guidelines for Acute ST-segment elevation myocardial infarction. Russian Journal of Cardiology. 2020;25(11):4103. doi: 10.15829/1560-4071-2020-4103
- Byrne R, Rossello X, Coughlan J, et al. 2023 ESC Guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). European Heart Journal. 2023;44(38):3720–3826. doi: 10.1093/eurheartj/ehad191
- Alekyan BG, Boytsov SA, Ganyukov VI, Manoshkina EM. Impact of the COVID-19 Pandemic on Myocardial Revascularization in Patients with Acute Coronary Syndrome in the Russian Federation. Rational Pharmacotherapy in Cardiology. 2022;18(4):411–419. EDN: BYSCRX doi: 10.20996/1819-6446
- Wu J, Mamas M, Rashid M, et al. Patient response, treatments, and mortality for acute myocardial infarction during the COVID-19 pandemic. Eur Hear J Qual Care Clin Outcomes. 2021;7(3):238–246. doi: 10.1093/ehjqcco/qcaa062
- Skopets IS, Vezikova NN, Malafeev AV, et al. Treatment of Patients with Acute Coronary Syndrome with ST Segment Elevation in Clinical Practice of the Republic of Karelia: the Results of 10-year Register. Rational Pharmacotherapy in Cardiology. 2020;16(5):780–786. EDN: KWNEVY doi: 10.20996/1819-6446
- Weight N, Moledina S, Rashid M, et al. Temporal analysis of non-ST segment elevation-acute coronary syndrome (NSTEACS) outcomes in 'young' patients under the age of fifty: A nationwide cohort study. Int J Cardiol. 2023;391:131294. doi: 10.1016/j.ijcard.2023.131294
- Baloch F, Arshad A, Sethi S, Tai J. Acute myocardial infarction from a lower-middle income country-A comprehensive report on performance measures and quality metrics using National Cardiovascular Data Registry. PLoS One. 2023;18(11):e0294396. doi: 10.1371/journal.pone.0294396
Supplementary files
